TriSalus Life Sciences, Inc.
HealthcareNASDAQ:TLSI · NASDAQ Global Market
+$0.13 today
Vol 0.32M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
115.8%
avg 136.1%
ROIC
-112.3%
avg -101.9%
ROA
-111.0%
avg -195.6%
Analysis
ROE is currently the strongest return metric at 115.8% versus its period average of 136.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mary T. Szela | Chief Executive Officer, President & Director | $769,837.00 | — | 62 | $1.07M | 2.81% |
Jodi Devlin | Chief of Clinical Strategy & Operations | $651,719.00 | — | 63 | $97,364.00 | 0.26% |
Jennifer L. Stevens | Chief Regulatory, Quality and Therapeutics Officer | $629,995.00 | — | 64 | $124,110.00 | 0.33% |
David Patience | Chief Financial Officer | $585,329.00 | — | 40 | $275,757.00 | 0.73% |
Richard Marshak | Chief Commercial Officer | $564,470.00 | — | 67 | $125,101.00 | 0.33% |
Andrea Marasso | Vice President of Marketing | — | — | — | — | — |
Bryan F. Cox | Chief of Research | — | — | 64 | $163,415.00 | 0.43% |
Richard Marshall | Medical Director | — | — | — | $125,101.00 | 0.33% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$3.61M
Sells
15
$135,808.24
Net Sentiment
+$3.47M
Net buying
Most Active
Szela Mary T
4 transactions
1–10 of 27
Analysis
Insiders reported 12 buys worth $3.61M and 15 sells worth $135,808.24 over the last 12 months. That adds up to net buying of $3.47M. Szela Mary T was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +51.9% | +35.3% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +51.9% over three years. Forward estimates point to Revenue at +35.3% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Prenetics Global Limited
NASDAQ:PRE
$367.72M
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Owlet, Inc.
NYSE:OWLT
$84.14M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Who manages TLSI?
TriSalus Life Sciences, Inc. (TLSI) lists 8 active executives. The top listed executive is Mary T. Szela, Chief Executive Officer, President & Director.
Are TLSI insiders buying or selling?
Recent insider activity shows net buying of $51.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.